AZ
AstraZeneca takes $445m hit to halt motavizumab
December 22, 2010Research and Development AZ, AstraZeneca, MedImmune, motavizumab, respiratory, respiratory syncytial virus
AstraZeneca has withdrawn a US licence application for its biologic respiratory treatment motavizumab in a move that will cost the …
FDA delays approval of AstraZeneca’s Brilinta
December 20, 2010Research and Development, Sales and Marketing AZ, AstraZeneca, Brilinta, Brilique, acute coronary syndrome
US regulators have delayed approving AstraZeneca’s antiplatelet tablet Brilinta (ticagrelor) because their want more information about a crucial clinical trial. …
AZ’s Brilique approved in Europe
December 7, 2010Sales and Marketing AZ, AstraZeneca, Brilique, Plavix, acute coronary syndromes, antiplatelet, atherothrombotic events, ticagrelor
European regulator have approved AstraZeneca’s oral antiplatelet Brilique (ticagrelor tablets). Brilique can now be used for the prevention of atherothrombotic …
AstraZeneca staff strike as pension talks breakdown
November 15, 2010Manufacturing and Production AZ, AstraZeneca, AstraZeneca UK Manufacturing, GMB, Hurdsfield Industrial Estate, pensions, strikes, unions
Workers at an AstraZeneca facility in the UK went back on strike for the eighth time last week after talks …
AstraZeneca dodges another Seroquel lawsuit
April 8, 2010Sales and Marketing AZ, Seroquel, US
AstraZeneca has defeated another US lawsuit seeking compensation for diabetes side-effects allegedly caused by its drug Seroquel. A US Federal …
AstraZeneca signs generics deal with Torrent
March 11, 2010AZ, generics
AstraZeneca have signed a license and supply agreement with Indian-based Torrent Pharma that will boost its generics portfolio. Torrent will …
Recentin disappoints in colorectal cancer
March 9, 2010Research and Development AZ, Cancer, Recentin, colorectal cancer
AstraZeneca’s developmental oncology drug Recentin has failed to meet its primary endpoint in a phase II/III study. The once-daily oral …
AstraZeneca signs deal with Rigel on RA treatment
February 17, 2010Research and Development AZ, Rigel, rheumatoid arthritis
AstraZeneca is looking to enter the lucrative rheumatoid arthritis market by in-licensing a phase II treatment.The global market for rheumatoid …
AZ licences late-stage depression candidate
December 8, 2009Sales and Marketing AZ, Targacept, depression
AstraZeneca is to pay $200 million up front for rights to a late-stage developmental drug aimed at sufferers from depression …
Edelman wins AstraZeneca oncology account
November 24, 2009Medical Communications AZ, Edelman
AstraZeneca has handed global PR responsibility for its oncology brands to communications agency Edelman. The deal includes the pharma company’s …
AstraZeneca withdraws filings for lung cancer drug
November 2, 2009Research and Development, Sales and Marketing AZ, zactima
AstraZeneca has withdrawn marketing applications for its lung cancer drug Zactima in Europe and the US after evaluating updated results …
AZ-BMS launch Onglyza in Europe
October 19, 2009Sales and Marketing AZ, BMS, DPP-4, Onglyza, diabetes
Bristol-Myers Squibb and AstraZeneca’s long-awaited type II diabetes drug Onglyza has been launched in the UK, its first European market.Designed …
AZ signs biomarker research deal
October 5, 2009Research and Development AZ, Cancer
A deal between AstraZeneca and Cancer Research UK is set to expand biomarker research into how new drugs behave in …
Chop and change for pharma production facilities
September 28, 2009Manufacturing and Production AZ, Teva
AZ strikes drug development deal with Nektar Therapeutics
September 22, 2009Research and Development AZ, Nektar
AstraZeneca has licenced two anti-constipation drug development programmes from Nektar Therapeutics in a deal that could be worth more than …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
